Jump to content
Powered by

Research alliance between French and German researchers

Scientists from Ulm and Paris have joined forces to develop new medications against malignant brain tumours. They also cooperate in the training of future cancer researchers.

The two-year research project will focus on developing betulinic acid, which is found in abundance in birch bark, into a cancer drug. As was recently discovered, betulinic acid triggers programmed cell death (apoptosis) in cancer cells.

Survival rates still poor

Model of betulinic acid (Photo: University Hospital Ulm)
The collaborative project involves a team of researchers led by Simone Fulda of the Ulm University Hospital for Children’s and Youth Medicine and a team led by Guido Kroemer of the Gustave Roussy Cancer Research Institute in Villejuif, close to Paris. According to Fulda, who coordinates the project, the chances of patients surviving malignant brain tumours such as the quite frequent glioblastomas, are quite poor.
The project was successful in the “Joint Transnational Programme on Cancer” call, a cooperative venture between the German Academic Exchange Service (DAAD) and the French Institut National du Cancer (INCa). The two organizations are hoping to promote the long-term cooperation between scientists from Germany and France as well as the training of future generations of cancer researchers.

wp, Source: University Hospital of Ulm - 20.12.2007 (p)
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-alliance-between-french-and-german-researchers